Recent publications have proposed revisions to disease classification criteria, new definitions of early diagnosis
and remission, as well as guidelines for implementing treat-to-target strategies for the management of patients with spondyloarthritis.
Despite developments leading to this practice-changing approach, the concept of treat to target for spondyloarthritis
has not yet been widely accepted or implemented in standard clinical care. By placing greater emphasis on
clinical features that manifest early in the disease process, the early and aggressive treatment of the most common forms
of spondyloarthritis (namely ankylosing spondylitis and psoriatic arthritis), has been shown to have favorable patient outcomes
in reducing synovial inflammation, delaying joint damage, and maintaining functional status. This article discusses
the recent concept of Treat to Target in spondyloarthritis and the importance of early diagnosis of both ankylosing spondylitis
(AS) and psoriatic arthritis (PsA). It also highlights the main outcome measures for spondyloarthritis patients
achieving treatment goals of low levels of disease activity or clinical remission.
Treat to target, ankylosing spondylitis, psoriatic arthritis, remission, disease activity